Search

Your search keyword '"Goldenberg H"' showing total 383 results
Start Over Author "Goldenberg H"
383 results on '"Goldenberg H"'

14. Abstract # 3109 Alterations in microglia and their interaction with adult newborn (neurogenic) cells in the hippocampus underlie the anti-depressive effects of electroconvulsive therapy (ECT)

Author

Rimmerman, N., primary, Reshef, R., additional, Ashkenazi, E., additional, Verdiger, H., additional, Ayoun, L., additional, Abaragil, M., additional, Pienica, C., additional, Goldenberg, H., additional, Arad, I., additional, Lazar, K., additional, and Yirmiya, R., additional

Published
2019
Full Text
View/download PDF

31. ChemInform Abstract: Inhibitors of Blood Platelet cAMP Phosphodiesterase. Part 4. Structural Variation of the Side-Chain Terminus of Water-Soluble 1,3- Dihydro-2H-imidazo(4,5-b)quinolin-2-one Derivatives.

Author

MEANWELL, N. A., primary, HEWAWASAM, P., additional, THOMAS, J. A., additional, WRIGHT, J. J. K., additional, RUSSELL, J. W., additional, GAMBERDELLA, M., additional, GOLDENBERG, H. J., additional, SEILER, S. M., additional, and ZAVOICO, G. B., additional

Published
2010
Full Text
View/download PDF

35. Human mAbs to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains.

Author

Pier, G. B., primary, Boyer, D., additional, Preston, M., additional, Coleman, F. T., additional, Llosa, N., additional, Mueschenborn-Koglin, S., additional, Theilacker, C., additional, Goldenberg, H., additional, Uchin, J., additional, Priebe, G. P., additional, Grout, M., additional, Posner, M., additional, and Cavacini, L., additional

Published
2007
Full Text
View/download PDF

50. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552.

Author

Harris, D N, Michel, I M, Goldenberg, H J, Hartl, K S, Allen, G T, Steinbacher, T E, Schumacher, W A, Han, W C, Hall, S E, and Floyd, D M

Abstract

SQ 33,261 ([1S-[1 alpha,2 alpha(Z),3 alpha,4 alpha]]-6-[3-[[2- [(phenylamino)carbonyl]hydrazono]methyl]-7-oxabicyclo[2.2.1]hept-2 - yl]-4-hexenoic acid) and SQ 33,552 ([1S-[1 alpha,2 alpha(Z),3 alpha,4 alpha]]-6-[3-[[[[(4- chlorophenyl)amino]carbonyl]hydrazono]methyl]-7- oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid) are potent thromboxane (Tx) A2 receptor antagonists. They inhibited platelet aggregation in platelet-rich plasma induced by the TxA2 mimetic, U-46,619 (10 microM), with IC50 values of 200 and 70 nM, respectively. Neither compound inhibited ADP (20 microM)-induced platelet aggregation (IC50 greater than 1000 microM). SQ 33,261 and SQ 33,552 competitively antagonized U-46,619-induced contraction of rat aortic strips with respective pA2 values of 9.0 and 10.1 and KB values of 1.2 and 0.1 nM. They also competitively antagonized U-46,619-induced contraction of guinea pig tracheal strips with pA2 values of 8.9 and 9.9 and KB values of 1.9 and 0.4 nM, respectively. SQ 33,261 and SQ 33,552 (p.o.) were potent inhibitors of U-46,619 (2 mg/kg i.v.)-induced death in mice with ID50 values of 8 and 1 micrograms/kg, respectively. SQ 33,261 and SQ 33,552 (0.2 mg/kg p.o.), also had long duration of action in this assay with 50% survival times of 7 and 15 hr, respectively. SQ 33,261 at 0.01 and 1.0 mg/kg i.v., inhibited arachidonic acid-induced bronchoconstriction and reversed arachidonic acid-induced hypertension to a hypotensive response. SQ 33,552 inhibited TxA2 synthase at high concentrations (IC50 = 307 microM), whereas SQ 33,261 was inactive. Neither compound inhibited cyclooxygenase or caused an elevation of platelet cyclic AMP levels.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1992

Catalog

Books, media, physical & digital resources
See catalog results